t(1;3)(p36;p21) as the Sole Clonal Abnormality in Refractory Acute Myeloid Leukemia

Bing Bai, MD, Gary Lu, MD, Shimin Hu, MD, PhD, C. Cameron Yin, MD, PhD


Acute myeloid leukemia (AML) is a heterogeneous group of diseases with a multitude of molecular genetic aberrations and variable clinical outcome. Clonal chromosomal abnormalities have been identified in over 50% of AML cases, and have been regarded as one of the most important prognostic markers. We present a case of a 56-year-old Hispanic man with AML with minimal differentiation. Morphologically, the bone marrow was hypercellular with trilineage hypoplasia and 80% blasts. Flow cytometry analysis showed that the blasts were of myeloid immunophenotype. Conventional cytogenetic analysis showed t(1;3)(p36;p21) as the sole cytogenetic abnormality in 5 of 20 metaphases analyzed. The patient received daunorubicin and cytarabine, and achieved first remission. He relapsed 4 months later, and was treated with fludarabine, cytarabine, idarubicin, and G-CSF, and consolidated with high-dose cytarabine. He then received matched related stem cell transplantation. However, the disease relapsed again, and the patient died 11 months after initial diagnosis. To our best knowledge, this is the first report of t(1;3)(p36;p21) as the sole cytogenetic abnormality.



t(1;3)(p36;p21), acute myeloid leukemia, refractory

Full Text:



Yin CC, Medeiros LJ, Bueso-Ramose CE. Recent advances in the diagnosis and classification of myeloid neoplasms – comments on the 2008 WHO classification. Int J Lab Hematol 2010;32(5):461-476.

Huret JL. t(1;3)(p36;p21). Atlas Genet Cytogenet Oncol Haematol. May 2002. URL: http://AtlasGeneticsOncology.org/Anomalies/


Sato Y, Izumi T, Kanamori H, et al. t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes, Chromosomes Cancer. 2002;34(2):186-192.

Tri NK, Xinh PT, Nagao H, et al. Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36;p21) at the third relapse. Genes, Chromosomes Cancer. 2002;35(4):365-367.

Offit K, Burns JP, Cunningham I, et al. Cytogenetic analysis of chimerism and leukemia/relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. Blood. 1990;75(6):1346-1355.

Whang-Peng J, Knutsen T, Jaffe ES, et al. Sequential analysis of 43 patients with non-Hodgkin’s lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood. 1995;85(1):203-216.

Shi G, Weh HJ, Martensen S, et al. 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia. Cytogenet Cell Genet. 1996;74(4):295-299.

Horsman DE, Connors JM, Pantzar T, et al. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes, Chromosomes Cancer. 2001;30(4):375-382.

Dave BJ, Nelson M, Pickering DL, et al. Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization. Cancer Genet Cytogenet. 2002;132(2):125-132.

Heim S, Mitelman F. Cancer Cytogenetics. 3rd ed. John Wiley & Sons, Inc., Hoboken, New Jersey, 2009.


  • There are currently no refbacks.